NCT07239895

Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells

Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Regend Therapeutics · Industry
• Sex: All
• Age: 28 Days – 18 Years
• Healthy volunteers: Not accepted

Summary

Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.

Detailed description

The study is co-sponsored by Regend Therapeutics and Shanghai Children's Hospital.

Conditions

• Pediatric Bronchiolitis Obliterans

Interventions

Type	Name	Description
BIOLOGICAL	Airway Basal Stem Cells	Airway Basal Stem Cells

Timeline

• Start date: 2025-11-11
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2025-11-20
• Last updated: 2026-01-14

Locations

1 site across 1 country: China